Peer-reviewed veterinary case report
Epirubicin chemo helps dogs with lymphoma live longer
By Elliott, J W et al.·Published in Veterinary and comparative oncology·2013·Small Animal Teaching Hospital, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma.
- Species:
- dog
Plain-English summary
A group of 97 dogs with lymphoma received a chemotherapy treatment that included a drug called epirubicin. Most of the dogs showed a complete response to the treatment, with a high success rate of 96%. On average, dogs lived for about 342 days after starting the treatment, although those with a specific type of lymphoma had shorter survival times. The treatment was generally well tolerated, with side effects similar to those seen with other common chemotherapy drugs. Overall, epirubicin proved to be a safe and effective option for treating this type of cancer in dogs.
People also search for: dog lymphoma treatment · epirubicin for dogs · chemotherapy side effects in dogs
Abstract
The aim of the study was to report the outcome of treatment of 97 dogs with lymphoma that received a multi-agent chemotherapy protocol containing epirubicin as the primary anthracycline. Seventy-five dogs received a 25-week protocol with no maintenance phase whilst 22 dogs received a maintenance phase. Complete response rate was 96% and time to first relapse (TTR) and overall survival (OS) time for all dogs were 216 and 342 days, respectively. Dogs with T-cell lymphoma and those classified as WHO substage b had significantly poorer OS times and TTR. The protocol was well tolerated with toxicity similar to doxorubicin-containing protocols. Epirubicin as part of a multi-agent protocol is safe and effective in the treatment of canine multicentric lymphoma. There is a high initial response rate and an overall median survival time that is similar to other published doxorubicin-containing protocols.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22372620/